# Inhibrx Reports First Quarter 2026 Financial Results
Canonical URL: https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results
Ticker: INBX
Company: Inhibrx
Source: Inhibrx
Published: 2026-05-14 20:02 EST
Original Source URL: https://inhibrx.investorroom.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-16 13:00 EST — [Inhibrx Announces Amended Loan Agreement with Oxford Finance, Expanding Total Facility to $500.0 Million](https://biopharmsignal.com/news/INBX/inhibrx-announces-amended-loan-agreement-with-oxford-finance-expanding-total-fac-d29cd85b) — Source: Inhibrx
- 2026-06-15 13:15 EST — [Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma](https://biopharmsignal.com/news/INBX/inhibrx-announces-u-s-fda-acceptance-of-bla-for-ozekibart-in-patients-with-conve-d0380d86) — Source: Inhibrx
- 2026-05-14 20:02 EST — [Inhibrx Reports First Quarter 2026 Financial Results](https://biopharmsignal.com/news/INBX/inhibrx-reports-first-quarter-2026-financial-results) — Source: Inhibrx
- 2026-05-11 12:00 EST — [Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy](https://biopharmsignal.com/news/INBX/inhibrx-reports-interim-phase-2-data-for-inbrx-106-in-first-line-hnscc-initial-results-demonstrate-potential-costimulatory-benefit-over-pd-1-monotherapy) — Source: Inhibrx
- 2026-05-08 20:00 EST — [Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC](https://biopharmsignal.com/news/INBX/inhibrx-to-host-webcast-presentation-to-provide-clinical-update-on-inbrx-106-hexagon-study-in-first-line-hnscc) — Source: Inhibrx
## Related News
- 2026-07-21 20:15 EST — BFRG — [BullFrog AI to Participate in Water Tower Research Fireside Chat on Thursday, July 23, 2026](https://biopharmsignal.com/news/BFRG/bullfrog-ai-to-participate-in-water-tower-research-fireside-chat-on-thursday-jul-78357ce8)
- 2026-07-21 20:05 EST — CLPT — [ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026](https://biopharmsignal.com/news/CLPT/clearpoint-neuro-to-announce-second-quarter-2026-results-august-3-2026-6e4f3c05)
- 2026-07-21 20:05 EST — TCMD — [Tactile Medical to Release Second Quarter of Fiscal Year 2026 Financial Results on August 10, 2026](https://biopharmsignal.com/news/TCMD/tactile-medical-to-release-second-quarter-of-fiscal-year-2026-financial-results--798d4004)
- 2026-07-21 20:05 EST — PIII — [P3 Health Partners Schedules Second Quarter 2026 Earnings Release and Conference Call](https://biopharmsignal.com/news/PIII/p3-health-partners-schedules-second-quarter-2026-earnings-release-and-conference-6c9bd8a7)
- 2026-07-21 12:05 EST — VRCA — [Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel](https://biopharmsignal.com/news/VRCA/verrica-pharmaceuticals-and-medomie-pharma-enter-into-exclusive-distribution-mar-abf61522)